259 related articles for article (PubMed ID: 23162790)
1. Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.
López-Requena A; Burrone OR; Cesco-Gaspere M
Front Oncol; 2012; 2():159. PubMed ID: 23162790
[TBL] [Abstract][Full Text] [Related]
2. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
3. Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V(L)/V(H) determinants.
Benvenuti F; Burrone OR
Gene Ther; 2001 Oct; 8(20):1555-61. PubMed ID: 11704816
[TBL] [Abstract][Full Text] [Related]
4. Anti-idiotypic antibodies and the induction of specific tumor immunity.
Nepom GT; Hellström KE
Cancer Metastasis Rev; 1987; 6(4):489-502. PubMed ID: 2450687
[TBL] [Abstract][Full Text] [Related]
5. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.
Campbell MJ; Carroll W; Kon S; Thielemans K; Rothbard JB; Levy S; Levy R
J Immunol; 1987 Oct; 139(8):2825-33. PubMed ID: 3498771
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
Kwak LW; Young HA; Pennington RW; Weeks SD
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
[TBL] [Abstract][Full Text] [Related]
7. [Idiotypes and the idiotypic network].
Youinou P
Presse Med; 1989 Dec 16-23; 18(42):2059-64. PubMed ID: 2481306
[TBL] [Abstract][Full Text] [Related]
8. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
9. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor.
Chen TT; Tao MH; Levy R
J Immunol; 1994 Nov; 153(10):4775-87. PubMed ID: 7525715
[TBL] [Abstract][Full Text] [Related]
10. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
[TBL] [Abstract][Full Text] [Related]
11. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
Davis TA; Hsu FJ; Caspar CB; van Beckhoven A; Czerwinsk DK; Liles TM; Taidi B; Benike CJ; Engleman EG; Levy R
Biol Blood Marrow Transplant; 2001; 7(9):517-22. PubMed ID: 11669219
[TBL] [Abstract][Full Text] [Related]
12. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
13. Idiotypic vaccination in B-cell malignancies.
Bianchi A; Massaia M
Mol Med Today; 1997 Oct; 3(10):435-41. PubMed ID: 9358470
[TBL] [Abstract][Full Text] [Related]
14. Comparison of humoral immune responses and tumor immunity in mice immunized with recombinant SV40 large tumor antigen and a monoclonal anti-idiotype.
Shearer MH; Bright RK; Kennedy RC
Cancer Res; 1993 Dec; 53(23):5734-9. PubMed ID: 7694794
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
16. Regulation of idiotype expression. II. The phenotypic diversity of T15 idiotype-bearing antibody to phosphorylcholine in response to T-dependent and T-independent antigens.
Strickland FM; Cronkhite RI; Cerny J
Immunology; 1989 May; 67(1):8-15. PubMed ID: 2737696
[TBL] [Abstract][Full Text] [Related]
17. Anti-idiotypic DNA vaccines for B-cell lymphoma therapy.
Benvenuti F; Cesco-Gaspere M; Burrone OR
Front Biosci; 2002 Jan; 7():d228-34. PubMed ID: 11779689
[TBL] [Abstract][Full Text] [Related]
18. Idiotypic analysis of anti-I-Ak monoclonal antibodies. III. T- and B-cell responses to anti-Ia idiotopes are not modulated by syngeneic anti-idiotypic monoclonal antibodies.
Phillips ML; Delovitch TL
Cell Immunol; 1985 Dec; 96(2):363-75. PubMed ID: 3879805
[TBL] [Abstract][Full Text] [Related]
19. Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses.
Forconi F; King CA; Sahota SS; Kennaway CK; Russell NH; Stevenson FK
Immunology; 2002 Sep; 107(1):39-45. PubMed ID: 12225361
[TBL] [Abstract][Full Text] [Related]
20. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma.
Tao MH; Levy R
Nature; 1993 Apr; 362(6422):755-8. PubMed ID: 8469286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
